Alimentary pharmacology & therapeutics
Cure8 research brief
Why This Matters
People hospitalized with ulcerative colitis who don’t meet classic severe-disease criteria can still face meaningful colectomy risk. Using a lower CRP cutoff might help clinicians identify more high-risk patients earlier.
Who Should Pay Attention
Hospitalized UC patients and their caregivers; gastroenterologists and inpatient IBD teams; clinicians deciding on escalation of therapy or surgical referral.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study examined 503 hospital admissions for acute ulcerative colitis (UC) and compared patients who met traditional Truelove and Witts Criteria (ASUC) with those who did not (NASUC).
After matching for objective disease severity and treatments, colectomy rates were similar between groups, suggesting that NASUC patients can still carry substantial short- and medium-term surgical risk.
The authors tested lowering the CRP threshold to ≥12 mg/L and found this would have reclassified about one-quarter of NASUC patients as ASUC and would have identified a substantial share of those who later required colectomy within one year.
The paper reports that a reduced CRP cutoff may improve capture of high-risk hospitalized UC patients who are missed by current criteria.
This report is presented as an abstracted research article in a peer-reviewed journal; the Cure8 note summarizes the abstract provided by PubMed and does not represent a full independent review of the full study methods or data.
Keep In Mind
This classification and the CRP threshold change come from a propensity-matched analysis reported in an abstracted journal article. It reflects retrospective, single-centre data and would need broader validation before changing guidelines or routine practice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAlimentary pharmacology & therapeutics
AuthorsAmirah Etchegaray, Naeman Goetz, Katherine Hanigan +6 more
InstitutionRoyal Brisbane and Women's Hospital, Brisbane, Australia.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 18, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lowering the C‐Reactive Protein ( CRP ) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity‐Matched Analysis
Lowering the CRP cutoff could help hospitals identify hospitalized UC patients at higher risk of needing surgery who are currently classified as less severe. That may affect monitoring and treatment decisions during...
Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Machine Learning-Based Prediction of Treatment Response to Vitamin D3 in Adolescents and Young Adults with Inflammatory Bowel Disease: A Prospective, Open-Label, Alternation-Based Comparative Study
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.